Gene-therapy research led by Bruce Levine and Carl June of the Perelman School of Medicine is profiled.
All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments.
KENNETT SQUARE — It’s a quaint image: a rural vet in a pick-up truck driving down a country lane to treat a sick cow or horse.
Media Contact:Holly Auer | email@example.com | 215-349-5659May 8, 2012
PHILADELPHIA — A $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray will establish a center focused on the treatment and prevention of cancers associated with hereditary BRCA mutations.
The Basser Research Center — BRC for BRCA — will support research on the BRCA1 and BRCA2 genes, harmful forms of which are linked to greatly increased risks of developing breast and ovarian cancer. The Center is named in honor of Mindy Gray’s sister, Faith Basser, who died of ovarian cancer at age 44.
PHILADELPHIA -- Steve Fluharty, the University of Pennsylvania’s senior vice provost for research, is participating in a new congressional program that will highlight federally funded science projects. Called the “Golden Goose Awards,” not just any projects will do; the program exists to draw attention to the sometimes-serendipitous nature of scientific progress.
Bruce Levine and Carl June of the Perelman School of Medicine are highlighted for their gene therapy research.
Mark Duggan of the Wharton School is cited for a research paper about unemployment.
NSAIDs and Cardiovascular Risk Explained, According to Studies From Penn's Perelman School of Medicine
After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.
Genetically Modified T Cell Therapy Shown to Be Safe, Lasting in Penn Medicine Study of HIV Patients
HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. The results provide a framework for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, and a wide variety of other diseases.